

Drug Monograph

Drug/Drug **DermacinRx[®] ZRM Pak[™] (lidocaine and dimethicone) kit/**
 Class: **Herpes Antiviral**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	DermacinRx [®] is available in a ZRM Pak [™] that contains 15 patches of Lidocaine 5% and 4 ounces of dimethicone cream 5%.	
Manufacturer:	PureTek Corporation, San Fernando, CA 91340	
Indications:	DermacinRx [®] ZRM Pak [™] is indicated for the relief of pain associated with post-herpetic neuralgia.	
Costs:	\$840.30 per kit of DermacinRx [®] ZRM Pak. <i>Wholesale Acquisition Cost</i>	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> Open Access <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Under Solicitation <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.
 Date: August 29, 2016